Formulation Optimization of Long-acting Depot Injection of Aripiprazole by Using D-optimal Mixture Design

References

1. 1.↵
   1. Cheng Y. H.,
   2. Illum L.,
   3. Davis S. S.,

   Schizophrenia and drug delivery system. J. Drug Target 2000, 8 ( 2), 107– 17.

   OpenUrlPubMed
2. 2.↵
   1. Wang L.,
   2. Kleiner L.,
   3. Venkatraman S.,

   Structure formation in injectable poly (lactide-co-glycolide) depots. J. Controlled Release 2003, 90, 345– 54.

   OpenUrlPubMed
3. 3.↵
   1. David A. S.,
   2. Adams C.,

   Depot antipsychotic medication therapy in the treatment of patients with schizophrenia: (1) Meta review; (2) Patient and nurse attitudes. Health Technology Assessment 2001, 5 ( 34).
4. 4.↵
   1. Gilbert P. L.,
   2. Harris M. J.,
   3. McAdams L. A.,
   4. Jeste D. V.,

   Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch. Gen. Psychiatry 1995, 52 ( 3), 173– 188.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Swainston Harrison T.,
   2. Perry C. M.,

   Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004, 64 ( 15), 1715– 1736.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Uzun S.,
   2. Kozumplik O.,
   3. Mimica N.,
   4. Folnegovic-Smalc V.,

   Aripiprazole: an overview of a novel antipsychotic. Psychiatr. Danub 2005, 17 ( 1–2), 67– 75.

   OpenUrlPubMed
7. 7.↵
   1. Haglund B. O.,
   2. Joshi R.,
   3. Himmelstein K. J.,

   An in situ gelling system for parenteral delivery. J. Controlled Release 1996, 41 ( 3), 229– 235.

   OpenUrl
8. 8.↵
   1. Kranz H.,
   2. Bodmier R.,

   A novel in situ forming drug delivery system for controlled parenteral drug delivery. Int. J. Pharm 2007, 332 ( 1–2), 107– 114.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Domb A. J.,
   2. Shikanov A.,

   Poly(sebacic acid-co-ricinoleic acid) biodegradable injectable in situ gelling polymer. Biomacromolecules 2006, 7 ( 1), 288– 296.

   OpenUrlPubMed
10. 10.↵
    1. Prabhu S.,
    2. Tran L. P.,
    3. Betageri G. V.,

    Effect of co-solvents on the controlled release of calcitonin polypeptide from in situ biodegradable polymer implants. Drug Deliv 2005, 12 ( 6), 393– 398.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Al-Tahami K.,
    2. Meyer A.,
    3. Singh J.,

    Poly lactic acid based injectable delivery systems for controlled release of a model protein, lysozyme. Pharm. Dev. Technol. 2006, 11, 79– 86.

    OpenUrlPubMed
12. 12.↵
    1. Dong W. Y.,
    2. Guo Y. Z.,
    3. Qui K. Y.,
    4. Gu Z. W.,
    5. Feng X. D.,

    In vitro degradation and controlled release behaviour of D,L-PLGA50 and PCL-b-D,L-PLGA50 copolymer microspheres. J. Controlled Release 2005, 107 ( 1), 53– 64.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Chandrashekar G.,
    2. Udupa N.,

    Biodegradable injectable implant systems for long term drug delivery using poly (lactic-co-glycolic) acid copolymers. J. Pharm. Pharmacol 1996, 48 ( 7), 669– 674.

    OpenUrlPubMedWeb of Science
14. 14.↵
    1. Davis S. S.,
    2. Ilum L.,

    Polymeric microspheres as drug carriers. Biomaterials 1988, 9 ( 1), 111– 115.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. Shive M. S.,
    2. Anderson J. M.,

    Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev 1997, 28 ( 1), 5– 24.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Yamaguchi K.,
    2. Anderson J. M.,

    In vivo compatibility of Medisorb 65/35 D-L-Lactide/Glycolide copolymer microspheres. J. Controlled Release 1993, 24, 81– 93.

    OpenUrlCrossRef
17. 17.↵
    1. Parikh R. H.,
    2. Parikh J. R.,
    3. Dubey R. R.,
    4. Soni H. N.,
    5. Kapadia K. N.,

    Poly(D,L-lactide-co-glycolide) microspheres containing 5-fluorouracil: optimization of process parameters. AAPS PharmSciTech 2003, 4 ( 2), E13.

    OpenUrlPubMed
18. 18.↵
    1. El-Malah Y.,
    2. Nazzal S.,
    3. Khanfar N. M.,

    D-optimal mixture design: optimization of ternary matrix blends for controlled zero-order drug release from oral dosage forms. Drug Dev. Ind. Pharm 2006, 32 ( 10), 1207– 1218.

    OpenUrlPubMed
19. 19.↵
    1. Mura P.,
    2. Furlanetto S.,
    3. Cirri M.,
    4. Maestrelli F.,
    5. Marras A. M.,
    6. Pinzauti S.,

    Optimization of glibenclamide tablet composition through the combined use of differential scanning calorimetry and D-optimal mixture experimental design. J. Pharm. Biomed. Res 2005, 37 ( 1), 65– 71.

    OpenUrl
20. 20.↵
    1. Pean J. M.,
    2. Venier-Julienne M. C.,
    3. Filmon R.,
    4. Sergent M.,
    5. Phan-Tan-Luu R.,
    6. Benoit J. P.,

    Optimization of HSA and NGF encapsulation yields in PLGA microparticles. Int. J. Pharm 1998, 166 ( 1), 105– 115.

    OpenUrl
21. 21.↵
    Indian Pharmacopoeia. Government of India, Ministry of Health and Family Welfare, Controller of Publications: Delhi, 1996; A-24.
22. 22.↵
    1. Shimokawa Y.,
    2. Akiyama H.,
    3. Kashiyama E.,
    4. Koga T.,
    5. Miyamoto G.,

    High performance liquid chromatographic methods for the determination of aripiprazole with ultraviolet detection in rat plasma and brain: Application to the pharmacokinetic study. J. Chromatogr., B 2005, 821 ( 1), 8– 14.

    OpenUrlCrossRef
23. 23.↵
    Impurities: guideline for residual solvents Q3 C (R3) ICH guidelines (http://www.ich.org/LOB/media/MEDIA423.pdf).
24. 24.↵
    Dimethyl sulfoxide (DMSO): A “new” clean, unique, superior solvent. American Chemical Society annual meeting: Washington, DC, 8 20–24, 2000 (www.gaylordchemical.com/bulletins/Vignes-ACS.pdf).
25. 25.↵
    1. Mottu F.,
    2. Laurent A.,
    3. Rugenacht D. A.,
    4. Doelker E.,

    Organic solvents for pharmaceutical parenterals and embolic liquids: a review of toxicity data. PDA J. Pharm. Sci. Technol 2000, 54 ( 6), 456– 469.

    OpenUrlAbstract/FREE Full Text